抗高血压的阿尔多氨酸合成酶抑制剂:一个突破,面对采用障碍的障碍
Luke J Laffin1,2, Steven E Nissen1,2
1Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America.
PLoS medicine
|February 9, 2026
概括
阿尔多氨酸合成酶抑制剂显著降低血压,为治疗高血压提供了一种新方法. 然而,由于成本和可访问性挑战,它们的广泛使用可能受到限制.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 失控的高血压是一个广泛的全球健康问题.
- 现有的抗高血压疗法不能完全解决不受控制的血压的流行.
- 氨酸- ангиотензин- алдостерон系统在血压调节中起着至关重要的作用.
研究的目的:
- 评估阿尔多氨酸合成酶抑制剂在降低血压方面的疗效.
- 评估阿尔多氨酸合成酶抑制剂作为高血压治疗的新治疗策略的潜力.
- 考虑影响这种新药类临床采用的因素.
主要方法:
- 研究阿尔多氨酸合成酶抑制剂的临床试验.
- 对阿尔多素合成途径的药理学研究.
- 来自患者队伍的血压降低数据的分析.
主要成果:
- 阿尔多氨酸合成酶抑制剂显著降低了血压.
- 这些药物有效地向氨酸-氨酸-氨系统的关键组成部分.
- 观察到的降血压效应在研究人群中强大.
结论:
- 阿尔多氨酸合成酶抑制剂代表了一种有前途的新型抗高血压药物.
- 它们降低血压的能力有可能改善高血压管理.
- 经济因素和医疗保健准入可能构成广泛实施的障碍.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
621
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
621
ATP Synthase: Structure
15.7K
ATP synthase or ATPase is among the most conserved proteins found in bacteria, mammals, and plants. This enzyme can catalyze a forward reaction in response to the electrochemical gradient, producing ATP from ADP and inorganic phosphate. ATP synthase can also work in a reverse direction by hydrolyzing ATP and generating an electrochemical gradient. Different forms of ATP synthases have evolved special features to meet the specific demands of the cell. Based on their specific feature, ATP...
15.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
559
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
559
ATP Synthase: Mechanism
17.3K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
17.3K
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Hypertension I: Introduction
953
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
953


